You are viewing: Latin America AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The Latin America AI in Life Science Market was valued at $425.6 Million in 2026 and projected to reach to $1294.1 Million by 2031, representing a compound annual growth rate of 24.9%. Latin America's AI in Life Science market is positioned for substantial growth, driven by increasing healthcare digitalization, rising pharmaceutical R&D investments, and government initiatives supporting healthcare innovation.

Latin America AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Latin America AI in Life Science Market Trends and Insights

  • This 24.9% compound annual growth rate reflects Latin America's increasing adoption of artificial intelligence across drug discovery, clinical diagnostics, and personalized medicine applications.
  • Latin America is leveraging AI technologies to address healthcare challenges, improve research efficiency, and enhance patient outcomes across the region. The growth trajectory in Latin America is driven by rising healthcare investments, expanding pharmaceutical R&D capabilities, and growing digital health infrastructure.
  • Latin America's life science sector is increasingly integrating machine learning and AI-powered analytics to accelerate innovation and reduce time-to-market for new therapeutics.
  • By 2031, Latin America is expected to establish itself as a significant hub for AI-driven life science solutions, supported by improving regulatory frameworks and cross-border collaboration initiatives..

Key Market Statistics

  • CAGR (2026-2031) 24.9% CAGR
  • Market Size, 2026 ~USD 425.6 Million
  • Forecast, 2031 ~USD 1294.1 Million
  • Geography Latin America

Latin America AI in Life Science Market Overview

Rapid Market Expansion :

Latin America's AI in Life Science market is projected to grow from $425.6 million in 2026 to $1,294.1 million by 2031, representing a 24.9% CAGR and demonstrating strong regional momentum in healthcare AI adoption.

Drug Discovery & Development :

AI technologies are accelerating drug discovery timelines across Latin America, enabling pharmaceutical companies and research institutions to reduce development costs and bring innovative treatments to market faster.

Clinical Diagnostics Innovation :

Latin American healthcare providers are increasingly deploying AI-powered diagnostic tools for disease detection and patient screening, improving diagnostic accuracy and enabling early intervention in underserved populations.

Personalized Medicine Adoption :

Growing investment in AI-driven personalized medicine is enabling Latin American clinicians to tailor treatments based on individual patient genetics and medical histories, improving therapeutic outcomes and patient satisfaction.

Latin America AI in Life Science Market Dynamics

  • The region's expanding biotech ecosystem and growing partnerships with global AI vendors are accelerating technology adoption across clinical and research settings. Key growth drivers include improving healthcare infrastructure, rising prevalence of chronic diseases, and Latin America's strategic focus on becoming a regional hub for life sciences innovation.
  • By 2031, the market will be dominated by applications in drug discovery, clinical diagnostics, and precision medicine, with Brazil and Mexico leading regional adoption and investment..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • Latin America's AI in Life Science market will grow from $425.6M (2026) to $1,294.1M (2031) at a 24.9% CAGR.
    • Latin America is accelerating AI adoption in drug discovery, diagnostics, and personalized medicine to improve healthcare outcomes.
    • Rising pharmaceutical R&D investments and digital health infrastructure are primary growth catalysts in Latin America.
    • Latin America is positioning itself as an emerging AI life science hub with improving regulatory support and regional collaboration.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    Latin America AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    Target Audience

    • Pharmaceutical & Biotech Companies : Evaluate market expansion opportunities in Latin America and identify regions with highest demand for AI-driven drug discovery and development solutions.
    • Healthcare IT & AI Vendors : Understand Latin American healthcare provider needs, purchasing behaviors, and technology adoption rates to refine product offerings and go-to-market strategies.
    • Investment & Private Equity Firms : Assess investment potential in Latin American life science AI startups and identify high-growth market segments with attractive valuations and exit opportunities.
    • Healthcare Providers & Hospital Networks : Benchmark AI adoption trends across Latin America and identify best-in-class diagnostic and personalized medicine solutions to enhance clinical capabilities.
    • Government & Healthcare Policy Makers : Leverage market data to inform healthcare innovation policies, funding priorities, and regulatory frameworks supporting AI adoption in Latin American life sciences.

    Key Companies in the Latin America AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Latin America vs. other regions

    HowLatin America compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 17877.5 Million · 25.7% wtd CAGR ·
    Europe
    ~USD 8828.7 Million · 26.4% wtd CAGR ·
    Asia Pacific
    ~USD 8208.2 Million · 26.7% wtd CAGR ·
    Middle East & Africa
    ~USD 1074 Million · 25.5% wtd CAGR ·

    Countries within Latin America - compare and drill down

    Country2025 size (native)
    BrazilUSD 1243.6 Million
    MexicoUSD 689 Million

    Country market size visualization

    Brazil
    USD 1243.6 Million
    Mexico
    USD 689 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America with country-level breakdowns for Brazil and Mexico, enabling accurate budget allocation and investment planning specific to high-growth markets.
    • Competitive Landscape Analysis : Understand key players, market share distribution, and competitive strategies tailored to Latin America's unique regulatory environment and healthcare infrastructure.
    • Growth Opportunity Identification : Identify emerging segments in drug discovery, clinical diagnostics, and personalized medicine with the highest growth potential and ROI in Latin American markets.
    • Strategic Partnership Insights : Discover collaboration opportunities with regional biotech firms, healthcare providers, and government agencies driving AI adoption across Latin America.
    • Regulatory & Market Entry Guidance : Access country-specific regulatory frameworks, reimbursement models, and market entry strategies essential for successful AI life science product launches in Latin America.

    Frequently asked questions

    What is the current market size of AI in Life Science in Latin America?

    Latin America's AI in Life Science market was valued at $425.6 million in 2026 and is projected to grow to $1,294.1 million by 2031.

    What is the expected growth rate for AI in Life Science in Latin America?

    Latin America's AI in Life Science market is expected to grow at a compound annual growth rate (CAGR) of 24.9% from 2026 to 2031.

    Which applications are driving AI adoption in Latin America's life science sector?

    Latin America is seeing significant AI adoption in drug discovery, clinical diagnostics, personalized medicine, and research efficiency optimization.

    What factors are accelerating AI in Life Science growth across Latin America?

    Key drivers in Latin America include increased healthcare investments, expanding pharmaceutical R&D capabilities, digital health infrastructure development, and improving regulatory frameworks.

    How is Latin America positioning itself in the global AI life science market?

    Latin America is emerging as a significant regional hub through cross-border collaboration, regulatory modernization, and integration of AI-powered analytics in life science innovation.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status